Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lead Pb 203 VMT-a-NET

A radioconjugate consisting of the human somatostatin receptor subtype 2 (SSTR2)-targeting peptide and Tyr3-octreotide (TOC) analog VMT-a-NET, in which the N-terminus of TOC is conjugated, via polyethylene glycol (PEG) linkers (PEG2), to the cyclen-based lead-specific chelator PSC and labeled with the gamma-emitting radioisotope lead Pb 203, with potential imaging activity of neuroendocrine tumors (NETs) using single photon emission computed tomography (SPECT)/computed tomography (CT). Upon administration of lead Pb 203 VMT-a-NET, the peptide moiety specifically targets and binds to SSTR2, which is present on the cell membranes of many types of NETs. This allows for visualization of SSTR2-positive cells upon SPECT/CT imaging. SSTR2 is overexpressed on NETs and their metastases while most other normal tissues express low levels of SSTR2.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[203Pb]Pb-PSC-PEG-T
[203Pb]PSC-PEG2-TOC
[203Pb]VMT-alpha-NET
203Pb-PSC-PEG2-TOC
203Pb-VMT-a-NET
lead Pb 203 PSC-PEG2-TOC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search